Author

E De Cock

Observed names: E de Cock, E. De Cock, E. De cock, ERWIN DE COCK, Erwin DE COCK, Erwin De Cock

Observed institutions: F. Hoffmann-La Roche AG, Odense University Hospital, United BioSource Corporation (United Kingdom), Centre Hospitalier Universitaire de Besançon, inVentiv Health Clinical, Asklepios Klinik St. Georg, Institute for Interdisciplinary Medicine, Roche (Spain), Asklepios, Concordia University, Charité – Universitätsmedizin Berlin

ORCID: 0000-0002-1623-9169

Observed ORCID: 0000-0002-1623-9169

OpenAlex ID: A5028295084

A time and motion study of subcutaneous versus intravenous trastuzumab in patients with HER 2‐positive early breast cancer

2016 · Erwin De Cock, Xavier Pivot, et al. · Cancer Medicine · 114

PDF

Time Savings with Rituximab Subcutaneous Injection versus Rituximab Intravenous Infusion: A Time and Motion Study in Eight Countries

2016 · Erwin De Cock, Persefoni Kritikou, et al. · PLoS ONE · 111

PDF

Valor umbral del coste por año de vida ganado para recomendar la adopción de tecnologías sanitarias en España: evidencias procedentes de una revisión de la literatura

2007 · Erwin De Cock, Marc Miravitlles, et al. · PharmacoEconomics Spanish Research Articles · 59

Cost-Effectiveness of Linezolid vs Vancomycin in Suspected Methicillin-Resistant Staphylococcus aureus Nosocomial Pneumonia in Germany

2009 · E. De Cock, W. A. Krueger, et al. · Infection · 45

Costs of managing anemia with erythropoiesis‐stimulating agents during hemodialysis: A time and motion study

2008 · Brigitte SCHILLER, Sheila DOSS, et al. · Hemodialysis International · 37

Cost-effectiveness of oral ibandronate compared with intravenous (i.v.) zoledronic acid or i.v. generic pamidronate in breast cancer patients with metastatic bone disease undergoing i.v. chemotherapy

2005 · E. De Cock, J. Hutton, et al. · Supportive Care in Cancer · 35

Cost-effectiveness of oral ibandronate versus IV zoledronic acid or IV pamidronate for bone metastases in patients receiving oral hormonal therapy for breast cancer in the United Kingdom

2005 · Erwin De Cock, John Hutton, et al. · Clinical Therapeutics · 32

Economic evaluation of duloxetine versus serotonin selective reuptake inhibitors and venlafaxine XR in treating major depressive disorder in Scotland☆

2009 · Ágnes Benedict, Jorge Arellano, et al. · Journal of Affective Disorders · 28

Cost-effectiveness of linezolid versus vancomycin for hospitalised patients with complicated skin and soft-tissue infections in Germany

2008 · Dirk Schürmann, Sonja V. Sorensen, et al. · The European Journal of Health Economics · 27

Incidence and Predictors of Success of Adalimumab Dose Escalation and De-escalation in Ulcerative Colitis: a Real-World Belgian Cohort Study

2018 · Saartje Van de Vondel, Filip Baert, et al. · Inflammatory Bowel Diseases · 25

PDF

Hepatitis B Management Costs in France, Italy, Spain, and the United Kingdom

2004 · Ruth E. Brown, Erwin De Cock, et al. · Journal of Clinical Gastroenterology · 25

Cost-effectiveness of linezolid versus vancomycin for hospitalized patients with complicated skin and soft-tissue infections in France

2009 · E. De Cock, S. Sorensen, et al. · Médecine et Maladies Infectieuses · 22

Results of a Time and Motion Survey Regarding Subcutaneous versus Intravenous Administration of Daratumumab in Patients with Relapsed or Refractory Multiple Myeloma

2021 · Mary Slavcev, Allison Spinelli, et al. · ClinicoEconomics and Outcomes Research · 21

PDF

A Budget Impact Model for Paclitaxel-eluting Stent in Femoropopliteal Disease in France

2012 · Erwin De Cock, Marc Sapoval, et al. · CardioVascular and Interventional Radiology · 21

PDF

Evaluating preference weights for the Asthma Symptom Utility Index (ASUI) across countries

2006 · Emuella M Flood, Erwin De Cock, et al. · Health and Quality of Life Outcomes · 20

PDF

Healthcare Resource Utilization for Anemia Management: Current Practice with Erythropoiesis-Stimulating Agents and the Impact of Converting to Once-Monthly C.E.R.A.

2008 · Ulrich Saueressig, Jonathan T.C. Kwan, et al. · Blood Purification · 19

Quantifying the administration and monitoring time burden of several disease-modifying therapies for relapsing multiple sclerosis in the United Kingdom: A time and motion study

2023 · David Rog, Wallace Brownlee, et al. · Multiple Sclerosis and Related Disorders · 17

PDF

Measuring the cost of a pediatric vaccine administration in the UK

2017 · S. Mokiou, B. Standaert, et al. · Vaccine · 16

PDF

Time Savings With Transtuzumab Subcutaneous (SC) Injection Verse Trastuzumab Intravenous (IV) Infusion: A Time and Motion Study in 3 Russian Centers

2014 · E. De Cock, Y.I. Pan, et al. · Value in Health · 12

PDF

An observational time and motion study of denosumab subcutaneous injection and zoledronic acid intravenous infusion in patients with metastatic bone disease: results from three European countries

2017 · Jean-Jacques Body, Francesca Gatta, et al. · Supportive Care in Cancer · 11

PDF

Prk1 Assessing Provider Time for Anaemia Management of Dialysis Patients Using Time & Motion Methods:a Multi-centre Observational Study in Europe

2002 · E De Cock, L Van Bellinghen, et al. · Value in Health · 10

PDF

Time savings associated with C.E.R.A. once monthly: a time-and-motion study in hemodialysis centers in five European countries

2013 · Erwin De Cock, Frank Dellanna, et al. · Journal of Medical Economics · 9

PDF

A Time and Motion Study Comparing Subcutaneous Pembrolizumab Versus Intravenous Pembrolizumab in Combination with Chemotherapy for the Treatment of Metastatic Non-small Cell Lung Cancer

2025 · Erwin De Cock, Sabine Oskar, et al. · Advances in Therapy · 8

PDF

Time Savings With Rituximab Subcutaneous (SC) Injection Vs Rituximab Intravenous (IV) Infusion: Final Analysis From a Time-and-Motion Study In 8 Countries

2013 · Erwin De Cock, Persefoni Kritikou, et al. · Blood · 7

Pod4: Cost-consequences of Orthopaedic Surgery in Haemophilia Patients With Inhibitors

2001 · C Green, E De Cock · Value in Health · 7

Works count: 98

Citation count: 791

H-index: 17

I10-index: 21